drugset / Trial / NCT02211417

Oral DS107 in Moderate to Severe Atopic Dermatitis

NCT02211417 ↗

Phase 2 Completed 102 enrolled Dignity Sciences Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will compare the safety and efficacy of Oral DS107 (2 g) to placebo in patients with moderate to severe atopic dermatitis. Oral DS107 (2 g) will be orally administered for 8 weeks, and will be compared against placebo. This study will enroll approximately 100 adult patients.

Timeline

Start
2015-01
Primary completion
2015-11
Completion
2015-12

Outcome

Missed primary endpoint

registry NUMBER Placebo: 0.12 Proportion of participants NUMBER Oral DS107 2g: 0.22 Proportion of participants NCT02211417 ↗

registry analysis (superiority test); Placebo vs Oral DS107 2g; p = 0.057; Cochran-Mantel-Haenszel NCT02211417 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject DIHOMO-GAMMA-LINOLENIC ACID Small molecule 2 g Oral

Indications